Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2026
Biotech
ESMO: Boehringer builds case for late-phase rival to Imdelltra
Boehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival to Amgen’s Imdelltra.
Nick Paul Taylor
Oct 23, 2026 10:30am
ESMO: Why Zentalis is already dreaming of launching WEE1 drug
Oct 23, 2026 10:15am
ESMO: Takeda’s $1B bet ‘absolutely’ pays off with ADC ph. 3 win
Oct 23, 2026 8:48am
ESMO: Merck and Moderna post phase 3 cancer vaccine data early
Oct 22, 2026 4:45pm
